###begin article-title 0
###xml 29 34 29 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GATA6</italic>
Genomic Profiling Identifies GATA6 as a Candidate Oncogene Amplified in Pancreatobiliary Cancer
###end article-title 0
###begin p 1
Conceived and designed the experiments: KK MB AM JP. Performed the experiments: KK MB JK RR ER YK SC GS. Analyzed the data: KK MB JK RR ER YK CG YC SC KS PW GS JP. Contributed reagents/materials/analysis tools: KM CK PW TH MV AM. Wrote the paper: KK MB JP.
###end p 1
###begin p 2
These authors are joint senior authors on this work.
###end p 2
###begin p 3
###xml 624 629 624 629 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GATA6</italic>
###xml 725 730 725 730 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GATA6</italic>
###xml 926 931 926 931 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GATA6</italic>
###xml 1137 1142 1137 1142 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GATA6</italic>
###xml 1302 1307 1302 1307 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GATA6</italic>
###xml 1421 1426 1421 1426 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GATA6</italic>
Pancreatobiliary cancers have among the highest mortality rates of any cancer type. Discovering the full spectrum of molecular genetic alterations may suggest new avenues for therapy. To catalogue genomic alterations, we carried out array-based genomic profiling of 31 exocrine pancreatic cancers and 6 distal bile duct cancers, expanded as xenografts to enrich the tumor cell fraction. We identified numerous focal DNA amplifications and deletions, including in 19% of pancreatobiliary cases gain at cytoband 18q11.2, a locus uncommonly amplified in other tumor types. The smallest shared amplification at 18q11.2 included GATA6, a transcriptional regulator previously linked to normal pancreas development. When amplified, GATA6 was overexpressed at both the mRNA and protein levels, and strong immunostaining was observed in 25 of 54 (46%) primary pancreatic cancers compared to 0 of 33 normal pancreas specimens surveyed. GATA6 expression in xenografts was associated with specific microarray gene-expression patterns, enriched for GATA binding sites and mitochondrial oxidative phosphorylation activity. siRNA mediated knockdown of GATA6 in pancreatic cancer cell lines with amplification led to reduced cell proliferation, cell cycle progression, and colony formation. Our findings indicate that GATA6 amplification and overexpression contribute to the oncogenic phenotypes of pancreatic cancer cells, and identify GATA6 as a candidate lineage-specific oncogene in pancreatobiliary cancer, with implications for novel treatment strategies.
###end p 3
###begin title 4
Author Summary
###end title 4
###begin p 5
###xml 280 285 280 285 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GATA6</italic>
###xml 299 304 <span type="species:ncbi:9606">human</span>
###xml 608 613 <span type="species:ncbi:9606">human</span>
Pancreatic cancer is a devastating disease, having among the lowest survival rates of any cancer. A better understanding of the molecular basis of pancreatic cancer may lead to improved rationale therapies. We report here the discovery of amplification (i.e. extra copies) of the GATA6 gene in many human pancreatic cancers. GATA6 is a regulator of gene expression and functions in the development of the normal pancreas. Our findings indicate that its amplification and aberrant overexpression contribute to pancreatic cancer development. GATA6 joins a growing list of cancer genes with key roles in normal human development but pathogenic roles in cancer when aberrantly expressed. Our discovery of GATA6 amplification provides a new foothold into understanding the pathogenic mechanisms underlying pancreatic cancer, and suggests new strategies for therapy by targeting GATA6 or the genes it regulates.
###end p 5
###begin title 6
Introduction
###end title 6
###begin p 7
###xml 355 358 355 358 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000081-Bardeesy1">[1]</xref>
Pancreatic cancer has among the highest mortality rates of any cancer, pointing to a critical need for more effective therapies. While much progress has been made in understanding pancreatic cancer pathogenesis, a more comprehensive characterization of molecular genetic alterations is needed to define new molecular targets and therapeutic opportunities [1].
###end p 7
###begin p 8
###xml 166 170 166 170 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 216 220 216 220 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AKT2</italic>
###xml 225 228 225 228 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MYB</italic>
###xml 286 292 286 292 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN2A</italic>
###xml 294 298 294 298 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 303 308 303 308 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMAD4</italic>
###xml 370 373 370 373 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000081-Maitra1">[2]</xref>
###xml 510 516 510 516 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN2A</italic>
###xml 521 526 521 526 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMAD4</italic>
###xml 535 538 535 538 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000081-Kamb1">[3]</xref>
###xml 539 542 539 542 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000081-Hahn1">[4]</xref>
Genomic DNA copy number alterations (CNAs) are frequent in pancreatic cancer, where they alter the dosage and expression of cancer genes. Amplified oncogenes include KRAS (also commonly activated by point mutation), AKT2 and MYB. Likewise, deleted tumor suppressor genes (TSGs) include CDKN2A, TP53 and SMAD4 (also inactivated by mutation and promoter hypermethylation) [2]. Mapping CNAs has become an important starting point for discovering new cancer genes, and indeed led to the original identification of CDKN2A and SMAD4 as TSGs [3],[4].
###end p 8
###begin p 9
###xml 92 95 92 95 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000081-Kozu1">[5]</xref>
###xml 256 260 256 260 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 262 268 262 268 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN2A</italic>
###xml 270 274 270 274 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 279 284 279 284 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMAD4</italic>
###xml 329 332 329 332 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000081-Rashid1">[6]</xref>
###xml 333 336 333 336 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000081-IacobuzioDonahue1">[7]</xref>
During development, the ventral portion of the pancreas arises from the primitive bile duct [5]. While less is known of extrahepatic bile duct cancers, they appear to share many features with pancreatic cancers, including frequent molecular alterations of KRAS, CDKN2A, TP53 and SMAD4, as well as global patterns of allelic loss [6],[7]. Because of their anatomic proximity and similar histologies, pancreatic and distal bile duct cancers can at times be difficult to distinguish, and from a clinical and research standpoint are often practically combined under the umbrella of pancreatobiliary cancer.
###end p 9
###begin p 10
###xml 135 138 135 138 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000081-Pollack1">[8]</xref>
###xml 139 142 139 142 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000081-Pinkel1">[9]</xref>
###xml 466 470 466 470 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000081-Heidenblad1">[10]</xref>
###xml 471 475 471 475 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000081-Bashyam1">[13]</xref>
###xml 952 956 952 956 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000081-Hahn2">[14]</xref>
###xml 1136 1141 1136 1141 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GATA6</italic>
###xml 763 772 <span type="species:ncbi:10090">nude mice</span>
###xml 877 883 <span type="species:ncbi:10090">murine</span>
###xml 1066 1075 <span type="species:ncbi:10090">nude mice</span>
Recently, array-based comparative genomic hybridization (array CGH) has provided a powerful approach to catalog CNAs in cancer genomes [8],[9]. Profiling pancreatobiliary cancers, however, presents unique technical challenges due to the strong stromal response, where tumor cells typically account for less than 20% of cells in the specimen. Not surprisingly, to date genomic profiling of pancreatic cancer has been largely confined to studies of derived cell lines [10]-[13]. Strategies to enrich for tumor cells from primary cancers include physical microdissection, which is both technically demanding and, with the low yield of genomic DNA, is subject to biases in subsequent target amplification. An alternative strategy is expanding tumors as xenografts in nude mice, which effectively enriches the tumor cell fraction to >95%, (with the remaining stromal cells being of murine origin), while preserving genomic alterations of the parental tumor [14]. Here, we apply genomic profiling to a set of pancreatic and distal bile duct cancers grown as xenografts in nude mice, where among other alterations we identify and characterize GATA6 as a novel candidate lineage-specific oncogene amplified in pancreatobiliary cancer.
###end p 10
###begin title 11
Results
###end title 11
###begin p 12
###xml 524 527 498 501 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000081-Pollack1">[8]</xref>
###xml 687 694 659 666 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pgen-1000081-t001">Table 1</xref>
###xml 817 824 789 796 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pgen-1000081-t001">Table 1</xref>
###xml 1007 1014 979 986 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pgen-1000081-t001">Table 1</xref>
###xml 1019 1028 991 1000 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pgen.1000081.s001">Figure S1</xref>
###xml 978 983 <span type="species:ncbi:9606">human</span>
To comprehensively catalog CNAs in pancreatobiliary cancers, we carried out array CGH-based genomic profiling of a set of 37 cancers (31 exocrine pancreatic cancers and 6 distal bile duct cancers) expanded as xenografts to enrich for tumor cells, using cDNA microarrays representing approximately22,000 genes with a median interprobe spacing of approximately15 Kb. We identified numerous CNAs, among which 17 focal high-level DNA amplifications (i.e. fluorescence ratios >/=3, corresponding to at least 5-fold amplification [8]) and 7 presumptive homozygous deletions (i.e. fluorescence ratios </=0.25) were particularly informative in pinpointing known or novel candidate cancer genes (Table 1). By profiling gene expression in parallel, we also defined the subset of amplified genes exhibiting elevated expression (Table 1), a characteristic of oncogenes. For a subset of presumptive homozygous deletions, we validated homozygous loss by polymerase chain reaction (PCR) using human gene-specific primers (Table 1 and Figure S1).
###end p 12
###begin title 13
High-level amplifications and homozygous deletions.
###end title 13
###begin p 14
Specimen(s) with high-level amplification or presumptive homozygous deletion.
###end p 14
###begin p 15
Includes low-level respective gain/loss at the same locus.
###end p 15
###begin p 16
Boldface indicates gene expression well-measured by microarray and elevated when amplified.
###end p 16
###begin p 17
Underlined genes are those confirmed homozygously deleted by PCR.
###end p 17
###begin p 18
Boundaries vary among specimens; minimum shared region indicated.
###end p 18
###begin p 19
43% of specimens exhibited homozygous deletion by PCR.
###end p 19
###begin p 20
###xml 471 475 471 475 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000081-Bergamaschi1">[15]</xref>
###xml 476 480 476 480 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000081-Kwei1">[17]</xref>
###xml 797 802 797 802 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GATA6</italic>
###xml 832 838 832 838 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CTAGE1</italic>
###xml 896 905 896 905 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-1000081-g001">Figure 1A</xref>
###xml 908 913 908 913 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GATA6</italic>
###xml 913 917 913 917 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000081-Suzuki1">[18]</xref>
###xml 1123 1127 1123 1127 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000081-Molkentin1">[19]</xref>
###xml 1137 1142 1137 1142 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GATA6</italic>
###xml 1193 1197 1193 1197 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000081-Decker1">[20]</xref>
###xml 1198 1202 1198 1202 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000081-Watt1">[21]</xref>
###xml 1261 1266 1261 1266 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GATA6</italic>
Among the focal amplifications, we identified gain at 18q11.2 in 19% of pancreatobiliary cancers (5 of 31 pancreatic, and 2 of 6 bile duct). Notably, we found gains spanning 18q11.2 to be less common in other tumor types we had profiled on the same array platform, including cancers of the breast (3 gains in 89 (3%) tumors, 1 in 49 (2%) cell lines), prostate (0 in 64 (0%) tumors), lung (4 in 76 (5%) tumors, 4 in 52 (8%) cell lines) and colon (1 in 29 (3%) cell lines) [15]-[17] (and unpublished data), and in these other tumor types the gains when present were not focal, suggesting the putative driver oncogene within this locus may be specific to pancreatobiliary cancer. Strikingly, the smallest shared region of amplification among the xenograft specimens spanned just two annotated genes, GATA6 (GATA binding protein 6) and CTAGE1 (cutaneous T-cell lymphoma (CTCL)-associated antigen 1) (Figure 1A). GATA6[18] belongs to the GATA factor family of transcriptional regulators, whose members are expressed in distinct developmental and tissue-specific patterns and regulate cell-restricted programs of gene expression [19]. Because GATA6 was known to regulate normal pancreas development [20],[21], we sought to explore a possible functional connection of GATA6 gene amplification and pancreatobiliary cancer.
###end p 20
###begin title 21
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GATA6</italic>
GATA6 is focally amplified in pancreatobiliary cancer.
###end title 21
###begin p 22
###xml 435 441 435 441 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CTAGE1</italic>
###xml 653 657 653 657 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000081-Kent1">[55]</xref>
###xml 694 699 694 699 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GATA6</italic>
###xml 704 710 704 710 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CTAGE1</italic>
###xml 736 741 736 741 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GATA6</italic>
###xml 843 846 843 846 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000081-Pollack1">[8]</xref>
###xml 871 876 871 876 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GATA6</italic>
###xml 969 973 969 973 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">left</italic>
###xml 980 985 980 985 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GATA6</italic>
###xml 1030 1036 1030 1036 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">center</italic>
###xml 1052 1057 1052 1057 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">right</italic>
###xml 1102 1107 1102 1107 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GATA6</italic>
(A) Genomic profiles by CGH on cDNA microarrays of pancreatic (P) and bile duct (B) cancer xenografts across cytoband 18q11.2. Genes are ordered by genome position. Red indicates positive tumor/normal aCGH ratios (scale shown), and samples called gained at 18q11.2 are marked below by closed circle (gains highlighted in yellow). Genes and ESTs (IMAGE clone ID shown) on the microarray residing within the amplicon core are indicated. CTAGE1 (asterisked) was not present on the array but resides where shown. (B) Genomic profile of B291 by CGH on an Agilent ultra high-definition custom microarray tiling 18q11.2, mapped onto the UCSC genome browser () [55]. The amplicon peak spans two genes, GATA6 and CTAGE1. (C) Q-PCR validation of GATA6 amplification in B291. Note, hybridization measurements by CGH tend to underestimate true CNA ratios [8]. (D) FISH validation of GATA6 amplification in the parent tumor (paraffin section) from which xenograft B291 was derived (left), and GATA6 gain in pancreatic cancer cell lines AsPC1 (center) and Panc3.27 (right). Gain is evident by the increased ratio of GATA6(red)/centromere-18(green) signals. DAPI (nuclear) counterstaining is shown in grayscale.
###end p 22
###begin p 23
###xml 365 370 365 370 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GATA6</italic>
###xml 375 381 375 381 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CTAGE1</italic>
###xml 383 392 383 392 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-1000081-g001">Figure 1B</xref>
###xml 413 418 413 418 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GATA6</italic>
###xml 466 475 466 475 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-1000081-g001">Figure 1C</xref>
###xml 498 505 498 505 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in situ</italic>
###xml 590 599 590 599 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-1000081-g001">Figure 1D</xref>
###xml 601 605 601 605 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">left</italic>
###xml 853 857 853 857 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000081-Bashyam1">[13]</xref>
###xml 860 869 860 869 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-1000081-g001">Figure 1A</xref>
###xml 924 933 924 933 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-1000081-g001">Figure 1D</xref>
A single bile duct cancer xenograft specimen (B291) with focal high-level DNA amplification was particularly informative in defining amplicon boundaries. Using a custom Agilent ultra-high definition CGH array with probes tiling 18q11.2 with an average 343nt spacing, we first confirmed the amplicon boundaries in B291, finding the amplicon peak indeed spanned just GATA6 and CTAGE1 (Figure 1B). We also validated GATA6 amplification in B291 by quantitative (Q)-PCR (Figure 1C), and by fluorescence in situ hybridization (FISH) in the parent tumor from which the B291 xenograft was derived (Figure 1D, left panel), the latter excluding the possibility of amplification arising during xenograft growth. Focal 18q11.2 gain was also present in 3 of 18 (17%) pancreatic cancer cell lines (AsPC1, Panc3.27 and Capan1) we had previously profiled by array CGH ([13]) (Figure 1A, and data not shown), a finding we confirmed by FISH (Figure 1D).
###end p 23
###begin p 24
###xml 35 40 35 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GATA6</italic>
###xml 100 109 100 109 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-1000081-g002">Figure 2A</xref>
###xml 173 182 173 182 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-1000081-g002">Figure 2B</xref>
###xml 184 185 184 185 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 279 288 279 288 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-1000081-g002">Figure 2C</xref>
###xml 339 345 339 345 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CTAGE1</italic>
###xml 635 644 635 644 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-1000081-g002">Figure 2D</xref>
###xml 744 753 744 753 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-1000081-g002">Figure 2E</xref>
###xml 1197 1198 1197 1198 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1209 1210 1207 1208 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 1218 1226 1216 1224 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-1000081-g003">Figure 3</xref>
###xml 1281 1290 1279 1288 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-1000081-g003">Figure 3E</xref>
###xml 1367 1368 1365 1366 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1380 1381 1376 1377 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 589 594 <span type="species:ncbi:9606">human</span>
Consistent with an oncogenic role, GATA6 exhibited increased mRNA expression by microarray in B291 (Figure 2A) and among the group of xenograft specimens with 18q11.2 gain (Figure 2B; P = 0.003, Mann-Whitney U-Test), a finding also confirmed by Q-reverse transcription (RT)-PCR (Figure 2C). In contrast, expression of the neighboring gene CTAGE1 was not detectable by Q-RT-PCR (data not shown). We also observed increased GATA6 protein levels by Western blot in pancreatic cancer cell lines with 18q11.2 gain, compared to pancreatic cancer cell lines without gain or to the nontumorigenic human pancreatic ductal epithelial line HPDE (Figure 2D), and by immunohistochemistry (IHC) in the parent tumor from which the B291 xenograft was derived (Figure 2E). To assess the frequency with which GATA6 exhibited elevated expression in primary pancreatic cancer, we performed IHC on a tissue microarray (TMA) that included cases of normal pancreas, pancreatitis and pancreatic ductal adenocarcinoma. We observed moderate and strong GATA6 nuclear staining respectively in 15 (28%) and 25 (46%) of 54 primary pancreatic cancers compared to just 3 (9%) and 0 (0%) of 33 normal pancreas specimens surveyed (P<0.001, chi2 test) (Figure 3). GATA6 expression was also elevated in pancreatitis (Figure 3E). There was no significant relation between GATA6 staining and tumor grade (P = 0.18, chi2 test).
###end p 24
###begin title 25
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GATA6</italic>
GATA6 is overexpressed when amplified.
###end title 25
###begin p 26
###xml 124 129 124 129 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GATA6</italic>
###xml 212 217 212 217 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GATA6</italic>
###xml 345 350 345 350 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GATA6</italic>
###xml 370 372 370 372 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">th</sup>
###xml 376 378 376 378 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">th</sup>
###xml 385 387 385 387 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">th</sup>
###xml 401 402 401 402 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 687 692 687 692 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GATA6</italic>
###xml 949 953 949 953 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">left</italic>
###xml 1028 1033 1028 1033 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">right</italic>
(A) Plot of DNA (by array CGH) vs. mRNA (by expression profiling) ratios for genes on chromosome 18 for specimen B291 shows GATA6 (indicated) to be the most highly expressed gene within the 18q11.2 amplicon. (B) GATA6 mRNA levels, measured by microarray, are elevated in pancreatobiliary xenografts with compared to without DNA gain at 18q11.2 (GATA6). Box plots show 25th, 50th and 75th percentiles; P-values (Mann-Whitney U-Test) for pairwise comparisons are indicated. (C) Q-RT-PCR validation of microarray-measured GATA6 transcript levels in eight specimens, four each with and without 18q11.2 gain. (D) Western blot analysis of representative pancreatic cancer cell lines indicates GATA6 (56 kD) is overexpressed at the protein level when amplified; GAPDH serves as a loading control. (E) IHC analysis of GATA6 protein expression (nuclear brown staining) indicates elevated expression in the parent tumor from which xenograft B291 was derived (left), in comparison to normal pancreatic duct from the same paraffin section (right).
###end p 26
###begin title 27
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GATA6</italic>
GATA6 is overexpressed in primary pancreatic tumors.
###end title 27
###begin p 28
###xml 256 257 256 257 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 296 297 296 297 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
###xml 298 299 298 299 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</italic>
###xml 318 319 318 319 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 605 626 605 626 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s4">Materials and Methods</xref>
###xml 722 723 722 723 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 734 735 732 733 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
Shown are representative IHC stains for GATA6 protein expression in (A) normal pancreas, and in pancreatic ductal adenocarcinoma with (B) absent, (C) moderate, and (D) strong nuclear staining. Filled arrowheads indicate pancreatic ductal epithelial cells (A), or pancreatic adenocarcinoma cells (B-D). Open arrowhead (A) shows non-specific cytoplasmic staining observed in pancreatic acinar cells. (E) Distribution of GATA6 expression among different diagnoses represented on the tissue microarray. The IHC staining score considers both staining intensity and fraction of cells with nuclear staining (see Materials and Methods). GATA6 expression is significantly elevated in pancreatic cancer compared to normal pancreas (P<0.001, chi2 test).
###end p 28
###begin p 29
###xml 231 235 231 235 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000081-Tusher1">[22]</xref>
###xml 419 428 419 428 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-1000081-g004">Figure 4A</xref>
###xml 534 538 534 538 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FGF1</italic>
###xml 543 547 543 547 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EVI1</italic>
###xml 585 589 585 589 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000081-Subramanian1">[23]</xref>
###xml 733 734 733 734 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 745 754 745 754 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-1000081-g004">Figure 4B</xref>
###xml 931 940 931 940 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-1000081-g004">Figure 4C</xref>
Since GATA6 is a transcriptional regulator, we sought to identify co-expressed genes, which might include its downstream transcriptional targets and suggest functional involvements. Using Significance Analysis of Microarrays (SAM) [22], we identified 86 genes whose expression was significantly (False discovery rate, FDR, <1%) increased (73 genes) or decreased (13 genes) in xenografts with elevated GATA6 expression (Figure 4A). The SAM-identified gene set spanned diverse biological processes, and included known cancer genes like FGF1 and EVI1. Gene Set Enrichment Analysis (GSEA) [23] confirmed an enrichment of putative upstream GATA factor binding sites among the genes whose expression correlated with elevated GATA6 levels (P = 0.004) (Figure 4B). Interestingly, by GSEA the top functional gene sets associated with elevated GATA6 expression all related to mitochondrial activities connected to oxidative phosphorylation (Figure 4C).
###end p 29
###begin title 30
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GATA6</italic>
GATA6 expression signature.
###end title 30
###begin p 31
###xml 648 649 648 649 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S</italic>
###xml 734 735 734 735 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 764 765 764 765 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S</italic>
(A) Heatmap representation of genes identified by SAM analysis with significantly (FDR<1%) increased (73 genes) or decreased (13 genes) expression in xenografts with GATA6 mRNA levels above the mean. Specimens are ordered by GATA6 expression level; genes are ordered in descending rank of their SAM score. Expression levels are indicated by colorimetric ratio-scale (shown). (B) GSEA identifies enrichment of genes with putative GATA binding sites in xenografts with GATA6 expression levels above the mean. Enrichment is evidenced by the early positive deflection of the Kolmogorov-Smirnov running sum. The significance of the maximum running sum (S) was evaluated by comparison to 500 trials with randomly permuted class labels; the P-value is the frequency that S in the actual data is equaled or exceeded in the permuted data. (C) Top ranking (FDR shown) functional gene sets identified by GSEA to be enriched in xenografts with above-average GATA6 expression levels. TCA: tricarboxylic acid (Krebs) cycle.
###end p 31
###begin p 32
###xml 50 55 50 55 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GATA6</italic>
###xml 231 236 231 236 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GATA6</italic>
###xml 350 355 350 355 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GATA6</italic>
###xml 421 425 421 425 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000081-Birmingham1">[24]</xref>
###xml 426 430 426 430 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000081-Jackson1">[25]</xref>
###xml 471 480 471 480 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-1000081-g005">Figure 5A</xref>
###xml 562 571 562 571 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-1000081-g005">Figure 5B</xref>
###xml 818 823 818 823 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GATA6</italic>
###xml 858 867 858 867 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-1000081-g002">Figure 2D</xref>
###xml 906 915 906 915 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-1000081-g005">Figure 5B</xref>
###xml 917 922 917 922 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">right</italic>
###xml 961 966 961 966 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GATA6</italic>
###xml 1186 1195 1186 1195 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-1000081-g005">Figure 5C</xref>
###xml 1226 1235 1226 1235 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-1000081-g005">Figure 5D</xref>
###xml 1325 1334 1325 1334 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-1000081-g005">Figure 5E</xref>
To directly assess the functional significance of GATA6 amplification and overexpression in pancreatic cancer, we used RNA interference (RNAi) to target GATA6 knockdown in two pancreatic cancer cell lines, AsPC1 and Panc3.27, with GATA6 gain and overexpression. Transfection of two independent On-TARGETplus short interfering RNAs (siRNAs) targeting GATA6, designed and chemically modified to minimize off-target effects [24],[25], led to decreased GATA6 protein levels (Figure 5A), and to decreased cell proliferation compared to a negative control siRNA pool (Figure 5B). While the reduction in cell proliferation was relatively modest, it was statistically significant and reproducible in multiple independent experiments (not shown). In contrast, siRNA transfection of a pancreatic cancer cell line, PL45, without GATA6 amplification and overexpression (Figure 2D) did not diminish cell proliferation (Figure 5B, right panel), supporting the specificity of GATA6 targeting. We examined in more detail the effect of GATA6 knockdown in AsPC1 cells, where the reduced cell proliferation was attributable to decreased cell-cycle progression (as evidenced by decreased S-phase fraction; Figure 5C) but not increased apoptosis (Figure 5D). GATA6 knockdown in AsPC1 cells also led to reduced colony formation in liquid culture (Figure 5E).
###end p 32
###begin title 33
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GATA6</italic>
GATA6 amplification/overexpression contributes to cell proliferation.
###end title 33
###begin p 34
###xml 105 110 105 110 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GATA6</italic>
###xml 117 122 117 122 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GATA6</italic>
###xml 438 443 438 443 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GATA6</italic>
###xml 468 469 468 469 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 480 481 480 481 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 506 511 506 511 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GATA6</italic>
###xml 699 700 699 700 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 726 731 726 731 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GATA6</italic>
###xml 957 959 957 959 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">th</sup>
###xml 972 974 972 974 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">th</sup>
###xml 987 988 987 988 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1086 1091 1086 1091 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">right</italic>
(A) Confirmation of siRNA-mediated knockdown of GATA6 in AsPC1 and Panc3.27 cells. Two different siRNAs (GATA6-1 and GATA6-2) were used to target GATA6, along with a non-targeting siRNA pool (control). GATA6 levels assayed by Western blot; GAPDH levels provide a loading control. (B) GATA6 knockdown results in decreased cell proliferation in reduced serum, measured by WST-1 assay, in cells with (AsPC1, Panc3.27) but not without (PL45) GATA6 gain/overexpression. *, P<0.05; **, P<0.01 (Student's t-test; GATA6 compared to control). (C) GATA6 knockdown reduces cell-cycle progression in AsPC1 cells, evidenced by decreased S-phase fraction following BrdU labeling, quantified by flow cytometry. *, P<0.05; (Student's t-test; GATA6 compared to control). (D) GATA6 knockdown does not significantly alter levels of apoptosis, quantified by annexin V staining. (E) GATA6 knockdown reduces colony growth of AsPC1 cells in liquid culture. Box plot illustrates 25th, mean and 75th percentile; P values (Student's t-test) indicated. Representative fields of Giemsa-stained colonies are shown (right).
###end p 34
###begin p 35
###xml 109 114 <span type="species:ncbi:9606">human</span>
In complementary experiments, we attempted to overexpress GATA6 by retroviral transduction in nontumorigenic human pancreatic ductal epithelial HPDE cells, and in the pancreatic cancer cell line PL45 harboring activated KRAS but no 18q11.2 gain. Though GATA6 expression was initially detected in infected cells by Western blot (data not shown), expression was lost upon expansion of cell pools under selection, suggesting GATA6 conferred negative fitness in these cell contexts.
###end p 35
###begin title 36
Discussion
###end title 36
###begin p 37
###xml 359 362 359 362 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MYC</italic>
###xml 374 378 374 378 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 393 397 393 397 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AKT2</italic>
###xml 437 443 437 443 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TGFBR2</italic>
###xml 457 463 457 463 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN2A</italic>
###xml 565 569 565 569 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TLR3</italic>
###xml 690 694 690 694 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000081-Rock1">[26]</xref>
###xml 695 699 695 699 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000081-Alexopoulou1">[27]</xref>
A main objective of our study was to comprehensively catalog CNAs in pancreatobiliary cancers. Genomic profiling of 31 pancreatic and 6 distal bile duct cancer xenografts identified numerous focal high-level DNA amplifications and homozygous deletions, thereby pinpointing known and candidate cancer genes. Known cancer genes included focal amplifications of MYC (8q24.21), KRAS (12p12.1) and AKT2 (19q13.2), and homozygous deletions of TGFBR2 (3p24.1) and CDKN2A (9p21.3). Other focal changes suggest entirely new pathobiology. For example, homozygous deletion of TLR3 (Toll-like receptor 3) (4q35.1), which functions in the innate immune response and is also highly expressed in pancreas [26],[27], suggests a possible role of infection in pancreatic carcinogenesis.
###end p 37
###begin p 38
###xml 56 61 56 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GATA6</italic>
###xml 271 275 271 275 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000081-Molkentin1">[19]</xref>
###xml 541 545 541 545 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000081-Molkentin1">[19]</xref>
###xml 546 550 546 550 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000081-Patient1">[28]</xref>
###xml 808 812 808 812 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000081-Decker1">[20]</xref>
###xml 813 817 813 817 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000081-Ketola1">[29]</xref>
###xml 931 935 931 935 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000081-Decker1">[20]</xref>
###xml 936 940 936 940 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000081-Watt1">[21]</xref>
###xml 948 953 948 953 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GATA6</italic>
###xml 1025 1030 1025 1030 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GATA6</italic>
###xml 1059 1064 1059 1064 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GATA6</italic>
###xml 595 600 <span type="species:ncbi:10090">mouse</span>
Prominent among novel oncogene candidates we identified GATA6 amplification at 18q11.2. GATA6 is one of six members of the mammalian GATA family of transcriptional regulators, each having two zinc finger domains and binding the common DNA sequence element (A/T)GATA(A/G) [19]. GATA factors 1-3 are expressed mainly in hematopoietic lineages, while GATA factors 4-6 are expressed in various tissues derived from mesoderm and endoderm, including the heart, liver, lung, gut, ovary and testis, where they function in cell lineage specification [19],[28]. In relation to pancreas development in the mouse, GATA4 and GATA6 are expressed in both endocrine and exocrine cell precursors, while in the adult pancreas expression of GATA4 and GATA6 is restricted to the exocrine and endocrine compartment, respectively [20],[29]. Recently, GATA4 and GATA6 have both been shown to be required for normal pancreas specification and development [20],[21]. While GATA6 has been linked to pancreas development, our findings now also connect GATA6 to pancreatic cancer, where GATA6 amplification and resultant overexpression contribute significantly (albeit at modest levels) to oncogenic phenotypes (cell proliferation, cell-cycle progression and colony formation) of pancreatic cancer cells.
###end p 38
###begin p 39
###xml 81 86 81 86 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GATA6</italic>
###xml 118 123 118 123 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GATA6</italic>
###xml 179 183 179 183 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000081-Capochichi1">[30]</xref>
###xml 184 188 184 188 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000081-Kamnasaran1">[31]</xref>
###xml 270 274 270 274 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000081-Kamnasaran1">[31]</xref>
###xml 387 391 387 391 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MITF</italic>
###xml 404 408 404 408 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000081-Garraway1">[32]</xref>
###xml 410 412 410 412 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AR</italic>
###xml 452 456 452 456 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000081-Visakorpi1">[33]</xref>
###xml 458 462 458 462 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ESR1</italic>
###xml 480 484 480 484 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000081-Holst1">[34]</xref>
###xml 504 510 504 510 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NKX2-1</italic>
###xml 512 516 512 516 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TITF</italic>
###xml 533 537 533 537 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000081-Kwei1">[17]</xref>
###xml 539 543 539 543 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000081-Tanaka1">[35]</xref>
###xml 544 548 544 548 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000081-Weir1">[37]</xref>
###xml 800 804 800 804 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000081-Garraway2">[38]</xref>
###xml 968 972 968 972 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000081-Lechner1">[39]</xref>
###xml 992 997 992 997 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GATA6</italic>
###xml 241 246 <span type="species:ncbi:9606">human</span>
Given its connection to development and cell specification, an oncogenic role of GATA6 might seem surprising. Indeed, GATA6 has been characterized as a TSG in other cell contexts [30],[31], and inactivating mutations have been identified in human malignant astrocytomas [31]. Nonetheless, other cell lineage-specific transcription factors have been found amplified in cancers, including MITF in melanoma [32], AR in hormone-independent prostate cancer [33], ESR1 in breast cancer [34], and most recently NKX2-1 (TITF) in lung cancer [17], [35]-[37]. The altered expression of such transcriptional regulators, having normal roles in lineage proliferation or survival, might be needed for tumor survival and progression in some cellular and genetic contexts, indicating a state of "lineage-dependency" [38]. More generally, the deregulated expression of transcription factors with roles in normal development reflects the principle of "oncology recapitulating ontogeny" [39]. While we detected GATA6 amplification primarily in pancreatobiliary cancers, GATA6 expression is not restricted to the developing pancreas, and therefore it remains to be determined whether GATA6 might have an oncogenic role in other cell lineages.
###end p 39
###begin p 40
###xml 208 212 208 212 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000081-Loercher1">[40]</xref>
###xml 355 359 355 359 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000081-Garraway1">[32]</xref>
###xml 457 461 457 461 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000081-Tanaka1">[35]</xref>
###xml 539 543 539 543 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000081-Kwei1">[17]</xref>
###xml 544 548 544 548 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000081-Weir1">[37]</xref>
###xml 190 195 <span type="species:ncbi:9606">human</span>
###xml 429 434 <span type="species:ncbi:9606">human</span>
###xml 641 646 <span type="species:ncbi:9606">human</span>
Another characteristic of lineage-specific oncogenes is that their oncogenic activity appears to be highly cell and genetic context dependent. MITF expression is growth inhibitory in normal human melanocytes [40], but in the context of BRAF activation (along with TP53 and RB1 pathway inactivation) leads to growth factor and anchorage independent growth [32]. Likewise, TITF1 is growth inhibitory when expressed in immortalized human lung epithelial cells [35], but promotes cell proliferation and survival when amplified in lung cancers [17],[37]. Consistent with these findings, GATA6 expression imparted negative fitness in immortalized human pancreatic ductal epithelial cells (HPDE), and in a pancreatic cancer cell line (PL45) with KRAS activation but no 18q11.2 gain. Additional studies are needed to clarify the genetic context of GATA6 oncogenic function.
###end p 40
###begin p 41
###xml 6 11 6 11 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GATA6</italic>
###xml 409 413 409 413 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000081-Algul1">[41]</xref>
###xml 666 671 666 671 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GATA4</italic>
While GATA6 was amplified in 19% of xenograft specimens, it was highly expressed at the protein level in 46% of primary pancreatic tumors surveyed. This finding suggests that GATA6 expression is likely elevated by mechanisms other than gene amplification in a substantial subset of cases. We also noted increased GATA6 expression in pancreatitis, which is a known risk factor for developing pancreatic cancer [41], and suggests a possible mechanistic link. As noted above, GATA4 is also expressed during normal pancreas development, though unlike GATA6 its expression is retained in the adult exocrine pancreas. Of interest, we have also observed DNA gains spanning GATA4 at 8p23.1 in a subset of xenografts (not shown), though none having focal DNA amplification. Additional studies are needed to examine the function, if any, of GATA4 in pancreatobiliary cancer.
###end p 41
###begin p 42
###xml 434 438 434 438 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000081-BirchMachin1">[42]</xref>
###xml 439 443 439 443 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000081-Galluzzi1">[43]</xref>
###xml 816 820 816 820 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000081-Monti1">[44]</xref>
Our analysis of gene-expression patterns correlated with GATA6 transcript levels has revealed an intriguing association with genes functioning in mitochondrial oxidative phosphorylation. Such altered mitochondrial activity might contribute to carcinogenesis through changes in cell metabolism, reactive oxygen species (ROS) production, or (through altered mitochondrial membrane potential) mitochondrial-associated apoptotic pathways [42],[43]. In the latter regard, it is notable in that we did not observe an effect of GATA6 knockdown on apoptosis, but rather on cell-cycle progression. While the exact connection to mitochondrial oxidative phosphorylation remains to be elucidated, it is of interest that a similar "OxPhos" expression pattern was recently identified in a subset of diffuse large B-cell lymphomas [44].
###end p 42
###begin p 43
###xml 104 108 104 108 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000081-Suzuki1">[18]</xref>
###xml 448 453 448 453 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GATA6</italic>
Since GATA6 is expressed in normal adult tissues like the endocrine pancreas, the lung, liver and heart [18], it is itself unlikely to become a useful target for therapy. However, future investigations will more precisely define the transcriptional effectors and pathways through which GATA6 mediates its oncogenic function, some of which might become important molecular targets. In conclusion, our genomic profiling and functional studies define GATA6 as a candidate lineage-specific oncogene in pancreatobiliary cancers, a finding which should lead to new opportunities for therapeutic intervention.
###end p 43
###begin title 44
Materials and Methods
###end title 44
###begin title 45
Specimens
###end title 45
###begin p 46
###xml 78 82 78 82 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000081-Hahn2">[14]</xref>
###xml 225 226 225 226 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 746 750 746 750 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000081-Liu1">[45]</xref>
###xml 355 360 <span type="species:ncbi:10090">mouse</span>
Pancreatic and distal bile duct cancer xenografts were generated as described [14] at the Johns Hopkins Hospital, with Institutional Review Board (IRB) and Institutional Animal Care and Use Committee approval. Briefly, a 1 mm3 piece of the primary tumor was soaked in Matrigel (Collaborative Biomedical Research), then implanted subcutaneously in a nu/nu mouse. Engrafted tumors were harvested when they reached 1-2 cm in diameter. Tumor cell enrichment was confirmed by H&E-stained frozen section. From adjacent pieces of the xenograft, DNA was isolated using the Qiagen DNeasy Tissue kit, and RNA using the Trizol (Invitrogen) method. Pancreatic cancer cell lines were obtained from the American Type Culture Collection, and the HPDE cell line [45] was kindly provided by Dr. Ming Tsao (University of Toronto).
###end p 46
###begin title 47
Array CGH and Expression Profiling
###end title 47
###begin p 48
###xml 175 179 175 179 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000081-Schuler1">[46]</xref>
###xml 338 342 338 342 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000081-Pollack2">[47]</xref>
###xml 343 347 343 347 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000081-Lapointe2">[48]</xref>
###xml 1114 1118 1098 1102 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000081-Demeter1">[49]</xref>
###xml 98 103 <span type="species:ncbi:9606">human</span>
###xml 138 143 <span type="species:ncbi:9606">human</span>
###xml 733 738 <span type="species:ncbi:9606">human</span>
cDNA microarrays were obtained from the Stanford Functional Genomics Facility and included 39,632 human cDNAs, representing 22,279 mapped human genes (18,049 UniGene clusters [46], together with 4,230 additional mapped ESTs not assigned UniGene IDs). Array CGH and expression profiling were performed according to our published protocols [47],[48]. For array CGH, 4 microg of genomic DNA from each test sample was random-primer labeled with Cy5 and co-hybridized to the microarray along with 4 microg of Cy3-labeled sex-matched normal leukocyte reference DNA from a single donor. For gene-expression profiling, 50 microg of total RNA from each sample and 50 microg of "universal" reference RNA (derived from 11 different established human cell lines) were differentially labeled with Cy5 and Cy3, respectively, and co-hybridized to cDNA microarrays. Following overnight hybridization and washing, arrays were imaged using a GenePix 4000B scanner (Molecular Devices). Fluorescence ratios were extracted using SpotReader software (Niles Scientific), and the data uploaded into the Stanford Microarray Database (SMD) [49] for storage, retrieval and analysis. The complete microarray datasets are available at SMD and at the Gene Expression Omnibus (GEO) (accession GSE11152).
###end p 48
###begin title 49
Microarray Data Analysis
###end title 49
###begin p 50
###xml 607 611 607 611 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000081-Tibshirani1">[50]</xref>
Background-subtracted fluorescence ratios were normalized by mean centering genes for each array. For array CGH analysis, we included for subsequent analysis only well-measured genes with Cy3 reference-channel fluorescence signal intensity at least 1.4-fold above background in at least 50% of samples. Map positions for arrayed cDNA clones were assigned using the NCBI genome assembly, accessed through the UCSC genome browser database (NCBI Build 36). For genes represented by multiple arrayed cDNAs, the average fluorescence ratio was used. DNA gains and losses were identified by the fused lasso method [50]. We defined high-level DNA amplifications and presumptive homozygous deletions as contiguous regions identified by fused lasso with at least 50% of genes displaying fluorescence ratios >/=3 or </=0.25, respectively. For expression profiling, fluorescence ratios were normalized for each array, and then well-measured genes (fluorescence intensities for the Cy5 or Cy3 channel at least 1.5-fold above background) were subsequently "mean-centered" (i.e. reported for each gene relative to the mean ratio across all samples).
###end p 50
###begin p 51
###xml 13 17 13 17 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000081-Tusher1">[22]</xref>
###xml 138 142 138 142 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000081-Subramanian1">[23]</xref>
###xml 172 176 172 176 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000081-Kim1">[51]</xref>
###xml 303 307 303 307 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000081-Kel1">[52]</xref>
###xml 482 486 482 486 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000081-Molkentin1">[19]</xref>
###xml 732 736 732 736 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000081-Subramanian1">[23]</xref>
SAM analysis [22] was performed using the 2-class method, comparing xenograft specimens with above and below mean GATA6 mRNA levels. GSEA [23] was carried out as described [51]. Genes with putative GATA binding sites (within the first 1-Kb upstream promoter sequence) were defined using MATCH software ([52]; default settings set to minimize false positives), applied to the common binding site matrix V$GATA_Q6 (all six GATA factors share a common DNA binding site, (A/T)GATA(A/G) [19]). To assess enrichment of GATA binding sites, the absolute value of the GSEA metric (Pearson correlation) was used in order to consider both upregulated and downregulated targets. GSEA using 522 functional gene sets was carried out as described [23].
###end p 51
###begin title 52
High-Definition 18q11.12 CGH Microarray
###end title 52
###begin p 53
###xml 98 102 98 102 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000081-Barrett1">[53]</xref>
A custom ultra high-definition CGH microarray was designed and obtained from Agilent Technologies [53]. The array included 4,362 probes tiling 1.5 Mb (Mb 17.5-19.0) of 18q11.2 with an average inter-probe spacing of 344 nt, and an additional 23,652 probes spanning the remaining genome for data normalization. DNAs were labeled as above, then hybridized to the Agilent array following the manufacturer's instructions, except using a 40 hr hybridization time (rather than the recommended 24 hr). Arrays were scanned using an Agilent G2505B scanner, and data extracted and normalized using Agilent Feature Extraction software (version 9.1) with default settings.
###end p 53
###begin title 54
PCR Assays
###end title 54
###begin p 55
###xml 38 45 38 45 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pgen-1000081-t001">Table 1</xref>
###xml 525 526 521 522 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 560 568 556 564 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pgen.1000081.s002">Table S1</xref>
###xml 787 795 767 775 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pgen.1000081.s002">Table S1</xref>
To validate homozygous deletions (see Table 1), we used gene-specific primer-pairs to PCR amplify genomic DNA from xenograft specimens. Primer-pairs for genes flanking the regions of homozygous deletion, and designed to have a distinguishable fragment size, were included in the PCR reactions as internal controls, and normal DNA was used as positive control for primer pairs. PCR was performed on an Applied Biosystems GeneAmp 9700, using 40 ng DNA template, 1x PCR buffer (Applied Biosystems), 200 microM dNTPs, 2.0 mM MgCl2, 10 pmol each individual primer (Table S1), and 1 U of AmpliTaq Gold DNA polymerase (Applied Biosystems) in a 10 microl reaction. The reaction conditions were: 95degreesC 10 min initial denaturation, followed by 35 cycles (94degreesC 30 s; annealing temp (see Table S1) 30 s; 72degreesC 30 s), and a final extension of 72degreesC 7 min. PCR products were resolved by gel electrophoresis on a 1.8% TAE agarose gel, and visualized using a UVP gel documentation system.
###end p 55
###begin p 56
###xml 12 17 12 17 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GATA6</italic>
###xml 497 501 473 477 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000081-Livak1">[54]</xref>
###xml 549 553 525 529 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NPC1</italic>
###xml 678 683 654 659 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GATA6</italic>
###xml 704 708 680 684 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NPC1</italic>
###xml 771 779 747 755 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pgen.1000081.s002">Table S1</xref>
To validate GATA6 amplification in B291, we carried out Q-PCR using the Quantitect SYBR Green PCR kit (Qiagen) on an ABI 7500 sequence detection system as per manufacturer's instructions. PCR was initiated at 95degreesC for 15 min (to activate the modified Taq polymerase), followed by a 40 cycle amplification (95degreesC 15 s, 58degreesC 30 s, 72degreesC 30 s). Melting curve analysis was performed to ensure specific PCR product while excluding primer dimers. We used the comparative CT method [54] to calculate relative DNA levels normalized to NPC1 (a gene located outside the 18q11.2 amplicon and not exhibiting CNA), which we then expressed as a ratio to the Ct value of GATA6 (also normalized to NPC1) obtained from normal DNA. PCR primer sequences are listed in Table S1.
###end p 56
###begin p 57
###xml 456 457 450 451 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 548 556 542 550 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pgen.1000081.s002">Table S1</xref>
To validate microarray-measured GATA6 mRNA levels, we carried out Q-RT-PCR using the QuantiTect SYBR Green RT-PCR Kit according to the manufacturer's instructions. The reaction mixture was first incubated at 50degreesC for 30 min for reverse transcription, then Q-PCR was carried out as above. For each specimen, relative levels of GATA6 transcript were calculated as the ratio of Ct value of GATA6 to that of GAPDH. Ratio values were then converted to log2 scale and normalized to the mean across all specimens. PCR primer sequences are listed in Table S1.
###end p 57
###begin title 58
FISH
###end title 58
###begin p 59
###xml 135 140 135 140 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GATA6</italic>
Probe labeling and FISH were performed using Vysis reagents according to the manufacturer's protocols. A locus-specific BAC mapping to GATA6 at 18q11.2 (RP11-1083G24; BACPAC Resources Centre) was labeled with SpectrumOrange, and co-hybridized with SpectrumGreen-labeled chromosome 18 centromere probe (CEP18; Vysis). Chromosomal locations of BACs were validated using normal metaphase slides (not shown). Slides were counterstained with DAPI, and imaged using an Olympus BX51 fluorescence microscope with Applied Imaging Cytovision 3.0 software.
###end p 59
###begin title 60
Immunohistochemistry
###end title 60
###begin p 61
###xml 804 809 <span type="species:ncbi:10090">mouse</span>
A tissue microarray (TMA) was constructed using a tissue arrayer (Beecher Instruments) and archived formalin-fixed, paraffin-embedded pancreatic tissue specimens from Stanford University, with IRB approval. The TMA contained 1.2 mm cores representing normal pancreas (33 cases), pancreatitis (16), other benign diagnoses (9), and pancreatic ductal adenocarcinoma (54). For immunohistochemistry, a 4 microm section was cut from the tissue microarray block, de-paraffinized in Citrisolv (Fisher Scientific), and hydrated in a graded series of alcohol solutions. Heat-induced antigen retrieval was performed by microwave pretreatment in citrate (1 mM, pH 6.0) for 15 minutes before staining. Endogenous peroxidase was blocked by preincubation with 1% hydrogen peroxide in phosphate-buffered saline. A GATA6 mouse monoclonal antibody (R&D systems) was used at 1:10 dilution for 30 min. Chromogenic detection was carried out using a peroxidase-conjugated secondary antibody and DAB reagents provided with the Envision detection kit (Dako). Nuclear staining intensity (absent, weak, medium, strong; 0-3 scale) and fractional epithelium staining (up to 25%, 50%, 75%, 100%; 1-4 scale) were each recorded, then summed for a final staining score.
###end p 61
###begin title 62
siRNA Transfections
###end title 62
###begin p 63
###xml 31 36 31 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GATA6</italic>
###xml 189 197 189 197 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pgen.1000081.s002">Table S1</xref>
On-TARGETplus siRNAs targeting GATA6, along with a negative control siRNA pool (ON-TARGETplus siCONTROL Non-targeting Pool), were obtained from Dharmacon. Sequences of siRNAs are listed in Table S1. Cell lines were maintained at 37degreesC in complete media of RPMI-1640 (Invitrogen), 10% FBS, 50 U/ml penicillin, and 50 U/ml streptomycin. For transfection, 100,000-250,000 cells were seeded per 6-well plate well, and transfected using Lipofectamine 2000 reagent (Invitrogen) according to the manufacturer's protocol. Cells were transfected with a final concentration of 50 nM siRNA for 6 hrs, subsequently replaced with reduced serum (2% FBS) growth media, where siRNA-mediated phenotypic effects were more reproducibly observed.
###end p 63
###begin title 64
Western Blot
###end title 64
###begin p 65
###xml 757 763 <span type="species:ncbi:9986">rabbit</span>
###xml 830 836 <span type="species:ncbi:9986">rabbit</span>
###xml 934 940 <span type="species:ncbi:9986">rabbit</span>
72 hours post-transfection, cells were lysed in 1x RIPA Lysis buffer (Upstate/Chemicon) supplemented with 1x Complete Protease Inhibitor (Roche, Indianapolis, IN), 0.1 mM sodium orthovanadate, 1 mM sodium fluoride and 1 mM PMSF, and protein quantified using the DC Protein Assay (Biorad). For Western blot, 25-40 microg protein lysate was electrophoresed on a 10% Tris/glycine polyacrylamide gradient gel (Biorad) and transferred to PVDF membrane (Biorad). After blocking in TBS-T buffer (20 mM Tris-HCl pH 7.4, 0.15 M NaCl, 0.1% Tween 20) with 5% dry milk for 30 min, blots were incubated sequentially with primary antibody at 4degreesC overnight, then HRP-conjugated secondary antibody at room temp for 45 min. Antibodies were used as follows: anti-GATA6 rabbit polyclonal antibody (1:200; Santa Cruz Biotechnology); anti-GAPDH rabbit polyclonal antibody (1:5,000 for loading control; Santa Cruz Biotechnology); HRP-conjugated anti-rabbit IgG (1:20,000, Pierce). Detection was carried out using the ECL kit (Amersham Biosciences).
###end p 65
###begin title 66
Cell Proliferation Assay
###end title 66
###begin p 67
###xml 248 250 248 250 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">th</sup>
24, 72 and 96 hours post-transfection, cell proliferation was quantified by colorimetry based on the metabolic cleavage of the tetrazolium salt WST-1 in viable cells, according to the manufacturer's protocol (Roche). WST-1 reagent was added at 1/10th the culture volume and incubated at 37degreesC for 30 min. Absorbance was then measured at 450 nm with reference to 650 nm using a Spectra Max 190 plate reader (Molecular Devices). Transfections were performed in triplicate and average (+/-1 SD) OD reported.
###end p 67
###begin title 68
Cell-Cycle Analysis
###end title 68
###begin p 69
72 hours post-transfection, cell-cycle distribution analysis was performed by flow cytometry using the BrdU-FITC Flow kit (BD Biosciences) per the manufacturer's instructions. Cells were incubated with 10 microM BrdU at 37degreesC for 4 hrs, then fixed and permeabilized with Cytofix/Cytoperm buffer (BD Biosciences). Cellular DNA was treated with DNase at 37degrees C for 1hr to expose incorporated BrdU, then cells were stained with anti-BrdU FITC antibody (to quantify incorporated BrdU) and 7-aminoactinomycin D (7-AAD; to quantify total DNA content). 10,000 events were scored by FACSCalibur (BD Biosciences) and analyzed using CellQuest software (BD Biosciences). Transfections were performed in triplicate and average (+/-1 SD) cell-cycle fractions reported.
###end p 69
###begin title 70
Liquid Colony Formation Assay
###end title 70
###begin p 71
24 hours post-transfection, 200 cells were plated each onto ten 10 cm dishes in complete media. After 2 weeks, surviving cells were stained with Giemsa (Sigma-Aldrich) for 15 min, and visible colonies counted on a light box.
###end p 71
###begin title 72
Apoptosis Assay
###end title 72
###begin p 73
72 hours post transfection, apoptosis was assayed by annexin V staining, quantified by flow cytometry using the Vybrant Apoptosis Assay kit (Invitrogen) as per the manufacturer's instructions. Floating cells and trypsinized adherent cells were pooled and resuspended in 200 microl annexin binding buffer. 2.5 microl Alexa Fluor 488 annexin V and 1 microl of 100 microg/ml propidium iodide (PI) solution were added and cells incubated for 15 min at room temp. Cells were then resuspended in equal volume of annexin binding buffer and analyzed immediately by flow cytometry. 10,000 events were scored by FACSCalibur and analyzed using CellQuest software. Transfections were performed in triplicate, and average (+/-1 SD) percent apoptosis reported.
###end p 73
###begin title 74
Supporting Information
###end title 74
###begin p 75
Representative PCR-validations of homozygous deletion. (A) 3p24.1 deletion. TGFBR2, located within the presumptive homozygous deletion, is PCR-amplified from normal genomic DNA, but not from pancreatic cancer xenograft P224. (B) 9p21.2 deletion. MOBKL2B, within the deletion, is PCR-amplified from normal genomic DNA but not from P201.
###end p 75
###begin p 76
(0.22 MB PDF)
###end p 76
###begin p 77
Click here for additional data file.
###end p 77
###begin p 78
Primer/siRNA sequences.
###end p 78
###begin p 79
(0.02 MB XLS)
###end p 79
###begin p 80
Click here for additional data file.
###end p 80
###begin p 81
###xml 250 257 <span type="species:ncbi:185739">Pollack</span>
We wish to thank the SFGF for microarray manufacture, the SMD for database support, Ilana Galperin (Stanford Cytogenetics Laboratory) for assistance with FISH analysis, and Eon Rios for assistance with FACS analysis. We also thank the members of the Pollack lab for helpful discussions.
###end p 81
###begin title 82
References
###end title 82
###begin article-title 83
Pancreatic cancer biology and genetics.
###end article-title 83
###begin article-title 84
Molecular pathogenesis of pancreatic cancer.
###end article-title 84
###begin article-title 85
A cell cycle regulator potentially involved in genesis of many tumor types.
###end article-title 85
###begin article-title 86
###xml 43 48 <span type="species:ncbi:9606">human</span>
DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1.
###end article-title 86
###begin article-title 87
Pancreatic development and anatomical variation.
###end article-title 87
###begin article-title 88
Cellular and molecular biology of biliary tract cancers.
###end article-title 88
###begin article-title 89
Large-scale allelotype of pancreaticobiliary carcinoma provides quantitative estimates of genome-wide allelic loss.
###end article-title 89
###begin article-title 90
Genome-wide analysis of DNA copy-number changes using cDNA microarrays.
###end article-title 90
###begin article-title 91
Array comparative genomic hybridization and its applications in cancer.
###end article-title 91
###begin article-title 92
Genome-wide array-based comparative genomic hybridization reveals multiple amplification targets and novel homozygous deletions in pancreatic carcinoma cell lines.
###end article-title 92
###begin article-title 93
High-resolution characterization of the pancreatic adenocarcinoma genome.
###end article-title 93
###begin article-title 94
Genomic DNA-chip hybridization reveals a higher incidence of genomic amplifications in pancreatic cancer than conventional comparative genomic hybridization and leads to the identification of novel candidate genes.
###end article-title 94
###begin article-title 95
Array-based comparative genomic hybridization identifies localized DNA amplifications and homozygous deletions in pancreatic cancer.
###end article-title 95
###begin article-title 96
Allelotype of pancreatic adenocarcinoma using xenograft enrichment.
###end article-title 96
###begin article-title 97
Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer.
###end article-title 97
###begin article-title 98
Genomic profiling reveals alternative genetic pathways of prostate tumorigenesis.
###end article-title 98
###begin article-title 99
Genomic profiling identifies TITF1 as a lineage-specific oncogene amplified in lung cancer.
###end article-title 99
###begin article-title 100
###xml 94 99 <span type="species:ncbi:9606">human</span>
A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer.
###end article-title 100
###begin article-title 101
The zinc finger-containing transcription factors GATA-4, -5, and -6. Ubiquitously expressed regulators of tissue-specific gene expression.
###end article-title 101
###begin article-title 102
###xml 35 40 <span type="species:ncbi:10090">mouse</span>
Gata6 is an important regulator of mouse pancreas development.
###end article-title 102
###begin article-title 103
Development of the mammalian liver and ventral pancreas is dependent on GATA4.
###end article-title 103
###begin article-title 104
Significance analysis of microarrays applied to the ionizing radiation response.
###end article-title 104
###begin article-title 105
Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.
###end article-title 105
###begin article-title 106
3' UTR seed matches, but not overall identity, are associated with RNAi off-targets.
###end article-title 106
###begin article-title 107
Position-specific chemical modification of siRNAs reduces "off-target" transcript silencing.
###end article-title 107
###begin article-title 108
###xml 12 17 <span type="species:ncbi:9606">human</span>
###xml 52 62 <span type="species:ncbi:7227">Drosophila</span>
A family of human receptors structurally related to Drosophila Toll.
###end article-title 108
###begin article-title 109
Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3.
###end article-title 109
###begin article-title 110
The GATA family (vertebrates and invertebrates).
###end article-title 110
###begin article-title 111
Transcription factor GATA-6 is expressed in the endocrine and GATA-4 in the exocrine pancreas.
###end article-title 111
###begin article-title 112
Anomalous expression of epithelial differentiation-determining GATA factors in ovarian tumorigenesis.
###end article-title 112
###begin article-title 113
###xml 77 82 <span type="species:ncbi:10090">mouse</span>
GATA6 is an astrocytoma tumor suppressor gene identified by gene trapping of mouse glioma model.
###end article-title 113
###begin article-title 114
Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma.
###end article-title 114
###begin article-title 115
###xml 71 76 <span type="species:ncbi:9606">human</span>
In vivo amplification of the androgen receptor gene and progression of human prostate cancer.
###end article-title 115
###begin article-title 116
Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer.
###end article-title 116
###begin article-title 117
Lineage-specific dependency of lung adenocarcinomas on the lung development regulator TTF-1.
###end article-title 117
###begin article-title 118
Oncogenic cooperation and coamplification of developmental transcription factor genes in lung cancer.
###end article-title 118
###begin article-title 119
Characterizing the cancer genome in lung adenocarcinoma.
###end article-title 119
###begin article-title 120
###xml 53 58 <span type="species:ncbi:9606">human</span>
Lineage dependency and lineage-survival oncogenes in human cancer.
###end article-title 120
###begin article-title 121
Perspective: cell differentiation theory may advance early detection of and therapy for lung cancer.
###end article-title 121
###begin article-title 122
MITF links differentiation with cell cycle arrest in melanocytes by transcriptional activation of INK4A.
###end article-title 122
###begin article-title 123
Mechanisms of disease: chronic inflammation and cancer in the pancreas-a potential role for pancreatic stellate cells?
###end article-title 123
###begin article-title 124
The role of mitochondria in ageing and carcinogenesis.
###end article-title 124
###begin article-title 125
Mitochondria as therapeutic targets for cancer chemotherapy.
###end article-title 125
###begin article-title 126
Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response.
###end article-title 126
###begin article-title 127
###xml 81 86 <span type="species:ncbi:9606">human</span>
Comparative phenotypic studies of duct epithelial cell lines derived from normal human pancreas and pancreatic carcinoma.
###end article-title 127
###begin article-title 128
###xml 65 70 <span type="species:ncbi:9606">human</span>
Pieces of the puzzle: expressed sequence tags and the catalog of human genes.
###end article-title 128
###begin article-title 129
###xml 112 117 <span type="species:ncbi:9606">human</span>
Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors.
###end article-title 129
###begin article-title 130
Gene expression profiling identifies clinically relevant subtypes of prostate cancer.
###end article-title 130
###begin article-title 131
The Stanford Microarray Database: implementation of new analysis tools and open source release of software.
###end article-title 131
###begin article-title 132
Spatial smoothing and hot spot detection for CGH data using the fused lasso.
###end article-title 132
###begin article-title 133
Combined microarray analysis of small cell lung cancer reveals altered apoptotic balance and distinct expression signatures of MYC family gene amplification.
###end article-title 133
###begin article-title 134
MATCH: A tool for searching transcription factor binding sites in DNA sequences.
###end article-title 134
###begin article-title 135
Comparative genomic hybridization using oligonucleotide microarrays and total genomic DNA.
###end article-title 135
###begin article-title 136
Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.
###end article-title 136
###begin article-title 137
###xml 4 9 <span type="species:ncbi:9606">human</span>
The human genome browser at UCSC.
###end article-title 137
###begin p 138
The authors have declared that no competing interests exist.
###end p 138
###begin p 139
This work was supported by grants from the NIH, CA112016 (JRP), CA09151 (KAK), GM07365 (KS), GI Cancer SPORE CA62924 (AM), from the Lustgarten Foundation (JRP), and by a core grant to the Centre for DNA Fingerprinting and Diagnostics by the Department of Biotechnology, Government of India (MDB). We also thank the family of Margaret Lee and the Sol Goldman Pancreatic Cancer Research Center for supporting the xenografting efforts at Johns Hopkins. MDB was supported in part by a Biotechnology Overseas Associateship from the Department of Biotechnology, Ministry of Science and Technology, Government of India. RR and SC were supported by a Senior Research Fellowship and a Junior Research Fellowship respectively from the Council for Scientific and Industrial Research, Government of India. None of the sponsors or funders had any role in the design and conduct of the study, in the collection, analysis, and interpretation of the data, or in the preparation, review, or approval of the manuscript.
###end p 139

